martes, 1 de mayo de 2018

Melanoma/Skin Cancer Detection and Prevention Month® (see related measures) 2 | National Quality Measures Clearinghouse 2/3

Search | National Quality Measures Clearinghouse

nqmc

Health Awareness Topics: May 2018

  • MEASURE SUMMARY
    •  
  • NQMC:011271
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their partial biopsy.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:011274
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with unresectable stage III and IV cutaneous melanoma who undergo systemic anti-cancer therapy (SACT).

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:007204
    •  
  • 2009 NOV

Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma for whom the pathology report documents the number of lymph nodes examined and the number of lymph nodes found to contain metastases.

American College of Surgeons
  • EXPERT COMMENTARY
    •  

Importance of Quality Metrics for Providing High Quality Melanoma Care

By: Karl Y. Bilimoria, MD, MS
  • MEASURE SUMMARY
    •  
  • NQMC:007201
    •  
  • 2009 NOV

Melanoma: percentage of patients who undergo an inguinal lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least five regional lymph nodes are resected and pathologically examined.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007198
    •  
  • 2009 NOV

Melanoma: percentage of patients with melanoma and clinically apparent/palpable lymphadenopathy for whom a lymph node dissection (LND) is performed without an antecedent histologic diagnosis.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:011266
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing clinical examination of relevant draining lymph node basins as part of clinical staging.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:007187
    •  
  • 2009 NOV

Melanoma: is the surgeon who performs sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma certified by the American Board of Surgery or equivalent board or international association?

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007207
    •  
  • 2009 NOV

Melanoma: percentage of patients who have stages 0, I, or IIA melanoma for whom an abdominal CT/MRI, pelvic CT/MRI, or PET scan was not performed, except in response to specific signs or symptoms.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:011269
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing partial biopsy who undergo a wide local excision.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:011263
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma who have their diagnostic excision biopsy carried out by a skin cancer clinician.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:011173
    •  
  • 2016 NOV

Melanoma: percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within the 12 month period, into a recall system.

American Academy of Dermatology; National Committee for Quality Assurance; Physician Consortium for Performance Improvement®
  • MEASURE SUMMARY
    •  
  • NQMC:007190
    •  
  • 2009 NOV

Melanoma: percentage of patients with a melanoma for whom a clear histologic margin is documented.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007210
    •  
  • 2009 NOV

Melanoma: percentage of patients with melanoma who have a metastatic lymph node detected on sentinel lymph node biopsy (SLNB) for whom a complete lymph node dissection (CLND) is performed except in the context of a clinical trial or if the patient has severe comorbidities.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007193
    •  
  • 2009 NOV

Melanoma: percentage of patients with a melanoma greater than or equal to 2 mm thick (i.e., T3 or T4) for whom the surgical excision margins are 2-3 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007199
    •  
  • 2009 NOV

Melanoma: percentage of patients who undergo a cervical lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least 15 regional lymph nodes are resected and pathologically examined.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:011272
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with unresectable stage III or IV cutaneous melanoma who have their BRAF status checked.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:007196
    •  
  • 2009 NOV

Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom the sentinel lymph nodes (SLNs) are examined with serial sectioning/hematoxylin and eosin (HE) and with immunohistochemistry (IHC) if the HE analysis is negative or equivocal (i.e., S-100, HMB-45, and MART-1).

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:011275
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing groin block dissection who have been referred to a lymphoedema service.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:007208
    •  
  • 2009 NOV

Melanoma: percentage of patients newly diagnosed with stage IV melanoma for whom a serum lactate dehydrogenase (LDH) level is measured.

American College of Surgeons
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)